OGT releases major CytoSure™ software update
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released a major new update to its CytoSure™ Interpret Software for array Comparative Genomic Hybridisation (aCGH) analysis. By utilising an entirely new relational database design, the software now allows sample data to be stored and analysed in accordance to its relationship with other data. For example, samples can be segregated into different projects by sample type or by user, thereby simplifying analysis. It can also perform common analysis steps automatically via the “Accelerate Workflow” mode, which significantly speeds up analysis, especially when working with a large number of samples. The intuitive graphical interface detects DNA regions exhibiting genomic variation, with results presented in an easy-to-use report, annotated with the relevant syndromes, genes, exons, and segmental duplications. This also includes links to external databases, putting each variation in context and helping to highlight the biological implications of the data generated. In addition, this latest software release incorporates a number of cancer annotation tracks, enabling meaningful interpretation of results obtained using OGT’s growing portfolio of CytoSure Cancer arrays.
Dr. Agne Liedén from the Department of Molecular Medicine and Surgery at the Karolinska Institutet, who has recently integrated the new CytoSure Interpret Software into his laboratory’s workflow, commented: “I have been extremely impressed with the ease-of-use and flexibility of the software. In our experience, OGT is very responsive to customer feedback and has produced an excellent software package.” OGT’s CEO, Dr Mike Evans, said: “The new update is part of OGT’s overall strategy, which is dedicated to providing products and services that convert complex datasets into easily interpretable, meaningful results. Our aim is to allow researchers to focus all of their time and energy on investigating the biology, rather than sifting through their data. In this case, constant innovation ensures that our CytoSure Interpret Software remains the industry-leading aCGH analysis software, and our dedicated software development team are continually implementing enhanced features and capabilities in response to customer feedback and new developments in the field.”
To complement OGT’s growing range of proprietary arrays containing both CNV and SNP probes, CytoSure Interpret Software can identify DNA regions exhibiting copy number variation, loss of heterozygosity and mosaicism. The latest update also provides a unique ‘Family Tree’ view, which makes it easy to examine inheritance patterns in up to three generations of the same family. In addition, to further ensure reliable, consistent results, the latest version of CytoSure Interpret Software incorporates permission-based account management. This allows individual users to be assigned specific, customisable access to system functionality and delivers a comprehensive audit trail of any workflow changes, thereby providing consistency of analysis and reporting.
For more information about OGT’s CytoSure Interpret Software, or the company’s other genomic and biomarker services and products, visit the new OGT website at www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Find out more
For more information about any OGT product or service, please contact us.